JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, M.-L.
Right arrow Articles by Stollar, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, M.-L.
Right arrow Articles by Stollar, V.
Journal of Virology, September 2004, p. 9645-9651, Vol. 78, No. 18
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.18.9645-9651.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

A Mutant of Sindbis Virus Which Is Able To Replicate in Cells with Reduced CTP Makes a Replicase/Transcriptase with a Decreased Km for CTP

Mei-Ling Li,1 Yen-Huei Lin,1,{dagger} H. Anne Simmonds,2 and Victor Stollar1*

Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey,1 Purine Research Unit, Guy's Hospital, London Bridge, Great Britain2

Received 30 December 2003/ Accepted 13 April 2004


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We reported earlier the isolation and characterization of a Sindbis virus mutant, SVPZF, that can grow in mosquito cells treated with pyrazofurin (PZF), a compound that interferes with pyrimidine biosynthesis (Y. H. Lin, P. Yadav, R. Ravatn, and V. Stollar, Virology 272:61-71, 2000; Y. H. Lin, H. A. Simmonds, and V. Stollar, Virology 292:78-86, 2002). Three amino acid changes in nsP4, the viral RNA polymerase, were required to produce this phenotype. We now describe a mutant of Sindbis virus, SVCPC, that is resistant to cyclopentenylcytosine (CPC), a compound that interferes only with the synthesis of CTP. Thus, in contrast to SVPZF, which was selected for its ability to grow in mosquito cells with low levels of UTP and CTP, SVCPC was selected for its ability to grow in cells in which only the level of CTP was reduced. Although SVPZF was cross-resistant to CPC, SVCPC was not resistant to PZF. Only one amino acid change in nsP4, Leu 585 to Phe, was required for the CPC resistance phenotype. The viral replicase/transcriptase generated in SVCPC-infected mosquito cells had a lower Km for CTP (but not for UTP) than did the enzyme made in SVSTD-infected mosquito cells. SVPZF and SVCPC represent the first examples of viral mutants selected for the ability to grow in cells with low levels of ribonucleoside triphosphates (rNTPs). Further study of these mutants and determination of the structure of nsP4 should demonstrate how alterations in an RNA-dependent RNA polymerase permit it to function in cells with abnormally low levels of rNTPs.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Sindbis virus (SV), an enveloped positive-strand RNA virus, is the prototype virus of the family Togaviridae, genus Alphavirus (see references 27 and 31 for reviews). The 11,703-nucleotide (nt)-long single-stranded genome has a 5' cap and a 3' poly(A) tail. The four nonstructural (ns) proteins are encoded by the 5' two-thirds of the viral genome, whereas the three structural proteins (the capsid protein, C, and the two envelope proteins, E1 and E2) are encoded by a subgenomic (SG) RNA whose sequence is colinear with the 3' one-third of the viral genome.

The four ns proteins, nsP1, nsP2, nsP3, and nsP4, are derived from the proteolytic cleavage of two large polyproteins, P123 and P1234. The latter is made by low-efficiency readthrough of an opal codon located near the 3' end of the nsP3 coding sequence.

Specific biochemical functions have been associated with three of the four ns proteins: nsP1 has both RNA methyltransferase and RNA guanylyltransferase activities and is thus involved in the modification of the 5' termini of the positive-strand genomic and SG RNAs (1, 21). The N-terminal domain of nsP2 has an RNA helicase activity (12), while the C-terminal domain is a protease (13) that serves to process the P123 and P1234 polyproteins. nsP2 also has an RNA-triphosphatase activity (32), thus associating it with the modification of the 5' termini of the viral positive-strand RNAs. Studies with a viral mutant, ts6 (2), and the presence of the consensus GDD motif have pointed to nsP4 as the viral RNA-dependent RNA polymerase (RDRP). The biochemical function of nsP3 is not known.

Synthesis of the positive-strand genomic RNA, and of the genomic size negative-strand RNA, and the transcription of the SG positive-strand RNA are regulated temporally by the processing of the ns polyproteins (17, 29). According to the model proposed by Lemm et al. (17), nsP4 and uncleaved P123 serve as the minus-strand RNA replicase. Cleavage of P123 results in the cessation of minus-strand synthesis and the more efficient synthesis of both genomic and SG plus-strand RNAs. More recently, Fata et al. (10) have suggested that the switch from minus-strand synthesis to the synthesis of SG RNA is associated with the cleavage of P23. The mechanism whereby the processing of P123 and P1234 regulates the synthesis of viral RNA is not known.

With the goal of identifying amino acid residues in nsP4 that influence the binding of ribonucleoside triphosphate (rNTP) substrates to the SV replicase/transcriptase, we had earlier isolated a mutant of SV, SVPZF, that is able to grow in Aedes albopictus cells treated with pyrazofurin (PZF), a pyrimidine analog that inhibits orotic acid decarboxylase, an enzyme in the pyrimidine biosynthetic pathway (20). Treatment of cells with PZF results in a reduction in the size of the UTP and CTP pools. Thus, SVPZF, in contrast to the parental virus, SVSTD, is able to grow in cells with lowered levels of UTP and CTP. We identified three amino acid changes in the SVPZF-encoded nsP4 protein, all of which are essential for the PZF resistance phenotype: Met 287 to Leu, Lys 592 to Ile, and Pro 609 to Thr. Since the three-dimensional structure of the alphavirus nsP4 protein had not been described, we derived a tentative structure for SV nsP4 by molecular modeling with the human immunodeficiency virus reverse transcriptase (14, 22) as the template. In this structure, residue 287 was localized to the finger domain of nsP4 and residues 592 and 609 were localized to the thumb domain.

SVPZF was selected on the basis of its ability to replicate in cells with decreased levels of both UTP and CTP. Could we now select a viral mutant on the basis of its ability to replicate in cells in which the level of only one of these rNTPs is decreased? If so, would such a mutant display the same amino acid changes in nsP4 as SVPZF? To answer these questions, we set out to select a viral mutant resistant to cyclopentenylcytosine (CPC), a compound that inhibits CTP synthase (11) and thus should decrease the level of CTP in treated cells. We expected that UTP levels in these cells would not be decreased, and might even be increased. We report here the properties of the mutant we obtained and identify the mutation responsible for the resistance to CPC.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cells and viruses. The A. albopictus mosquito (C7-10) cells used have been described previously (7); they were grown at 28°C in Eagle's minimal essential medium (MEM) supplemented with nonessential amino acids and 5% fetal calf serum. BHK cells were grown in Eagle's MEM supplemented with 5% tryptose phosphate and 5% bovine serum. The chicken embryo fibroblasts (CEF) used were either primary cultures (30) or the SL-29 cell line obtained from the American Type Culture Collection. CEF were grown in Eagle's MEM supplemented with 10 mM sodium pyruvate, 5% tryptose phosphate, and 5% bovine serum at 37°C.

Our standard virus (SVSTD) was derived from the HR strain of SV (28). SVToto is the virus derived from plasmid Toto1101 (23). Mosquito cells were infected at a multiplicity of infection (MOI) of 2 to 5 PFU per cell and maintained after infection at 34.5°C in medium containing 0.2% bovine serum albumin in place of fetal calf serum. Media from infected cultures were harvested at the indicated times, and virus titers were measured by plaque formation on CEF.

pToto1101 (13,638 bp) is a plasmid that contains a genome length cDNA copy of SV RNA immediately downstream from an SP6 promoter (23). Infectious RNA transcripts generated from pToto were used to transfect C7-10 cells as described previously (19).

Plasmid construction and site-directed mutagenesis. DNA manipulations were performed by standard procedures (24). The chimeric plasmid pToto:SVCPC5262-7999 was generated as follows. To prepare SVCPC cDNA, BHK cells were infected with SVCPC at an MOI of 1 PFU per cell at 34.5°C for 24 h. Total RNA was extracted from cells with Trizol reagent (Invitrogen, Carlsbad, Calif.). SVCPC cDNA was then synthesized by reverse transcription-PCR with 5 µg of the total RNA extracted from the infected cells, the SuperScript one-step reverse transcription-PCR system (Invitrogen), and the oligonucleotides nt 5161 to 5178 (plus strand) and 8049 to 8028 (minus strand) of the SV RNA sequence as upstream and downstream primers, respectively. The cDNA was digested with SpeI (nt 5262) and AatII (nt 7999) and cloned into pToto1101, replacing the original pToto sequence. The QuikChange kit (Stratagene, La Jolla, Calif.) was used to perform site-directed mutagenesis in accordance with the manufacturer's directions.

Extraction and analysis of ribonucleotides. Mosquito cells were either left untreated or treated with 5 µM CPC for 8 h; ribonucleotides were extracted from cells as described previously (4). Briefly, cells from each 35-mm-diameter plate were lysed with 200 µl of 10% trichloroacetic acid. The precipitate was removed by centrifugation for 1 min at 12,000 x g. The supernatant was back extracted with diethyl ether to a pH of 5, and the ribonucleotides were analyzed by high-performance liquid chromatography (9).

Determination of the Kms of the viral replicase/transcriptase for UTP and CTP. Confluent mosquito cells were infected with either SVSTD or SVCPC at an MOI of 1 PFU per cell. Twenty-four hours after infection, the p15 fraction was prepared as described by Lemm et al. (16). The p15 pellet isolated from one 100-mm-diameter dish was resuspended in 80 µl of storage buffer (10 mM Tris-Cl [pH 7.8], 10 mM NaCl, 15% glycerol). The polymerase assay was carried out as described by Lemm et al. (16). Briefly, 25 µl of the p15 fraction (equal to 9.4 x 106 cells) was used in a 50-µl reaction mixture. The concentration of the nucleotide under study was varied from 0 to 500 µM. To determine the Km for CTP, each reaction mixture contained 1 mM (each) ATP and GTP, 0.1 mM UTP, 5 µCi of [3H]UTP (36.2 Ci/mmol), and various concentrations of CTP. A similar reaction was set up to determine the Km for UTP, except that in this case, the concentration of CTP was 0.1 mM, 5 µCi of [3H]CTP (20.5 Ci/mmol) was added, and the concentration of UTP was varied. The reaction mixtures were incubated at 30°C for 20 min. Incorporation of the labeled isotope was linear for up to 40 min. The labeled RNA products were captured on nitrocellulose membrane and quantified by liquid scintillation counting (33). Reactions were also carried out with p15 fractions from mock-infected cells. The data points in Fig. 4A and B represent values obtained after subtraction of the "incorporation" observed with p15 proteins from mock-infected cells. The Km values were calculated with GraphPad Prism version 3.0 (GraphPad Software Inc., San Diego, Calif.).



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 4. Kinetic analyses of in vitro viral RNA synthesis by the SVCPC and SVSTD replicase/transcriptases. The assays were performed with p15 fractions from virus-infected mosquito cells as described in Materials and Methods. Nonlinear regression analysis with the GraphPad Prism version 3.0 software was used to calculate the Kms of the SV polymerase for CTP (A) and UTP (B). Each reaction was done in triplicate.

 

   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Effect of CPC on nucleotide pools. Figure 1 shows the effect of CPC on the pool size of the four rNTPs in A. albopictus cells. In both the zero time sample and the 8-h untreated sample, the ATP level was higher than that of any of the other rNTPs. After ATP, the pool sizes decreased in the order UTP > CTP > GTP. These results are similar to those we reported previously (29a), except that in the present studies the level of CTP is higher than the level of GTP. In extracts of cells treated with CPC for 8 h, the levels of ATP, UTP, and GTP all rose significantly whereas the level of CTP was drastically reduced. Thus, CPC selectively reduces the level of CTP.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 1. Effect of CPC on the rNTP pools in C7-10 cells. rNTP concentrations are expressed as picomoles per 106 cells initially plated. Extraction and analysis of rNTPs were done as described in Materials and Methods.

 
Selection of an SV mutant resistant to CPC. As shown in Fig. 2, CPC markedly reduced the yield of SVSTD from mosquito cells. At a concentration of 3 µM CPC, the yield was reduced more than 100-fold, and at 10 µM, it was reduced more than 1,000-fold.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 2. Effect of CPC on yield of SVSTD from mosquito cells. A. albopictus mosquito cells were infected with SVSTD at an MOI of 5 PFU per cell. After an adsorption period of 60 min, the virus was removed, the cultures were refed with medium, and CPC was added to the indicated concentrations. After incubation for 24 h at 34°C, samples of the medium were harvested and assayed for infectious virus by plaque formation on primary CEF.

 
To obtain a mutant resistant to CPC, a serial undiluted passage of SV in mosquito cells was carried out in the presence of a gradually increasing concentration of CPC. The passage was begun with SVSTD and continued for 34 passages; the first four passages were carried out in the presence of 1 µM CPC, and the last seven passages were done with 10 µM CPC. Intermediate concentrations of CPC were used for the intervening passages. For each passage, virus was harvested 20 to 24 h after infection and infected cells were maintained at 34°C. At various passage levels, the stocks were assayed for resistance to CPC. The desired level of resistance in the passaged virus populations was not obtained until more than 30 passages had been carried out. After 34 passages the virus was plaque purified and a working stock was prepared on primary CEF. This stock was designated SVCPC and used in all of the experiments described in this report. In contrast to SVSTD, which produced large plaques (3 mm in diameter), the plaques produced by SVCPC were only 1 mm in diameter.

Figure 3 shows that whereas 5 µM CPC reduced the yield of SVSTD by almost 300-fold, the same concentration of CPC reduced the yield of SVCPC by only 4- to 5-fold. Thus, SVCPC shows good resistance to CPC, implying that it can replicate well in cells with a markedly reduced level of CTP.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 3. Effect of CPC on yields of SVSTD and SVCPC from mosquito cells. The procedure was the same as that described for Fig. 2, except that the MOI was 2 PFU per cell.

 
Do SVPZF and SVCPC show cross-resistance? Mosquito cells infected with SVSTD, SVCPC, or SVPZF were treated with 5 µM CPC or 3 µM PZF or left untreated. Medium was harvested after 24 h and assayed for infectious virus by plaque assay on chick cells. As shown in Table 1, the yields of SVSTD from CPC- and PZF-treated cells were reduced approximately 350- and 600-fold, respectively. In contrast, neither PZF nor CPC reduced the yield of SVPZF. Consistent with the results shown in Fig. 2, SVCPC showed the expected resistance to CPC; however, it was as sensitive as SVSTD to PZF. Thus, SVPZF is cross-resistant to CPC but SVCPC is not cross-resistant to PZF.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Cross-resistance of SVPZF to CPCa

 
Identification of the mutation(s) responsible for resistance to CPC. Since we had shown earlier that the mutations responsible for the resistance of SVPZF to PZF, i.e., to decreased levels of UTP and CTP, were in the nsP4 coding sequence, it was likely that the mutations responsible for the resistance of SVCPC to CPC, i.e., to decreased CTP, would also lie in this region. Accordingly, we prepared a chimeric plasmid of pToto1101 that contained the full-length wild-type SV genome sequence, but with the cDNA sequence from nt 5262 to nt 7999 replaced with the SVCPC sequence (20), and used it to generate infectious RNA. The sequence from nt 5262 to nt 7999 contains all of the coding information for nsP4 and approximately half of nsP3. The virus (SVToto:CPC:5262-7999) obtained from this infectious RNA, like SVCPC, was resistant to CPC (data not shown).

Sequencing of the region from nt 5262 to nt 7999 revealed two mutations. The first, A5750C, changed the opal codon near the end of the nsP3 coding sequence to Cys, and the second, A7523C, changed Leu 585 of nsP4 to Phe. Since earlier work had shown that a change of the opal codon to an amino acid codon did not lead to any obvious phenotype or to an increase in the level of nsP4 (18), and since the mutation found in the opal codon of SVPZF was not required for the resistance of that mutant to PZF, it was likely that the drug resistance phenotype of SVCPC was due to the A7523C mutation. When this single mutation was introduced into SVToto, the resulting virus showed a resistance to CPC similar to that of SVCPC (Table 2). Thus, in contrast to SVPZF, which required three amino acid changes to produce resistance to PZF, SVCPC required only a single amino acid change to produce resistance to CPC. It is notable that whereas SVCPC produced small plaques, SVToto:nsP4:L585F gave rise to large plaques.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Phenotypes of recombinant virus and virus with the SVCPC mutationa

 
When the plaque purification was done that gave rise to SVCPC (after the 34 serial undiluted passages described above), other plaques were also picked. Three of these were characterized, and like SVCPC, they were resistant to CPC; furthermore, all three had the same A7523C mutation as SVCPC. According to the molecular model of nsP4 that we proposed earlier (20), residue 585 of nsP4 should be located in the thumb domain of nsP4.

We next determined the effects of other amino acid changes at position 585 of nsP4. Accordingly, mutations were introduced into pToto that were predicted to change Leu 585 of nsP4 to Tyr, Arg, His, Trp, Val, or Ala. As shown in (Table 3), only SVToto:nsP4:L585F and SVToto:nsp4:L585Y, viruses with the Phe and Tyr substitutions, respectively, were resistant to CPC. Like SVCPC, SVToto:nsP4:L585Y produced small plaques, but as noted above, SVToto:nsP4:L585F produced large plaques. Virus with His or Val in place of Leu 585 of nsP4 was sensitive to CPC. However, whereas the former produced large plaques, the latter produced a mixture of large and small plaques. None of the mutant viruses were resistant to PZF. We were not successful in obtaining viable virus when Trp, Arg, or Ala was substituted for Leu 585 of nsP4 and assume that these substitutions were lethal.


View this table:
[in this window]
[in a new window]
  		TABLE 3. Phenotype of SV with different amino acids at position 585 of nsP4a

 
Kinetic constants of the replicase/transcriptases encoded by SVCPC and SVSTD. We next determined the kinetic parameters for the viral replicase/transcriptases encoded by SVCPC and SVSTD. Since the p15 fractions from SV-infected cells make both genomic and SG viral RNAs (2, 3), the RNA-synthesizing activity we measured is referred to as a replicase/transcriptase. The Kms for CTP and UTP were measured as described in Materials and Methods.

Figure 4A shows the replicase/transcriptase activities (as measured by incorporation of [3H]UTP) of the SVCPC and SVSTD enzymes made in infected mosquito cells as a function of the concentration of CTP. The Kms for CTP as determined from the plot were 3.0 and 16.3 µM, respectively, for the SVCPC and SVSTD replicase/transcriptases. Thus, the Km for CTP of SVCPC polymerase is approximately 5.4-fold lower than that of SVSTD, consistent with the idea that the SVCPC replicase/transcriptase has a higher affinity for CTP than does the SVSTD replicase/transcriptase. Figure 4B shows a plot of the replicase/transcriptase activities made in SVCPC- and SVSTD-infected cells as a function of the concentration of UTP. The Kms for UTP of the two enzyme activities were quite similar, 10.1 and 12.5 µM, respectively. Similar Km values were obtained when the data were analyzed by Lineweaver-Burk plots.


   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Although rNTPs are the immediate precursors for the synthesis of viral RNA, there have been few studies of how manipulation of the rNTP pools affects the replication of RNA viruses. Critical questions include the following: how much can the rNTP pools be reduced before the synthesis of viral RNA is affected, what are the relative sensitivities of viral and host RNA syntheses to depletion of the rNTP pools, does the size of the rNTP pools vary from cell type to cell type, and could such variation influence the efficiency of viral replication and perhaps even the permissiveness of a cell for viral replication?

In this report we have shown that CPC, a compound that interferes with the synthesis of CTP, markedly reduced the size of the CTP pool in A. albopictus mosquito cells; this reduction in the size of the CTP pool was associated with a significant lowering of the yield of virus from treated cells. It is reasonable to assume that the level of CTP in the CPC-treated cells was too low to support efficient synthesis of viral RNA by the viral replicase/transcriptase.

Earlier work in our laboratory over a period of years has shown that by depleting mosquito cells of a metabolite that is the substrate of a virus-coded enzyme, it is possible to isolate viral mutants able to replicate in cells with low levels of that substrate. To the best of our knowledge, there are only five low-molecular-weight metabolites that are substrates for enzymes encoded by SV. These are ATP, GTP, UTP, and CTP, which are substrates for the viral RDRP (nsP4), and S-adenosylmethionine, which is a substrate for the viral RNA methyltransferase. GTP is a substrate not only for the RDRP but also for the viral RNA guanylyltransferase or capping enzyme. Thus, we isolated SVLM21, which is able to grow in cells presumably depleted of S-adenosylmethionine (8), and SVMPA, which is able to grow in cells depleted of GTP (25). The findings that the mutations responsible for both the SVLM21 and SVMPA phenotypes mapped to the nsP1 coding region provided the first evidence associating nsP1 with the capping and methylation of the viral mRNAs (21, 26). Similarly, SVPZF was isolated on the basis of its ability to grow in cells depleted of UTP and CTP. As expected, the mutations responsible for the ability of SVPZF to grow under these conditions were in the nsP4 coding sequence (20).

In this report we describe the isolation and properties of SVCPC, a mutant selected for its ability to grow in cells depleted only of CTP. In contrast to the situation with SVPZF, only one amino acid change was needed to enable the virus to grow in CTP-depleted mosquito cells, but as was the case with SVPZF, the amino acid change was in nsP4. However, the amino acid residue that was changed in SVCPC was different from those changed in the case of SVPZF.

It is notable that both SVPZF and SVCPC were found to have a mutation near the end of the nsP3 coding sequence eliminating the opal termination codon. However, abolishing this termination codon does not appear to increase the amount of nsP4 in infected cells (18) but would give rise to a slightly longer form of nsP3. Furthermore, site-directed mutagenesis clearly indicated that resistance to PZF or CPC did not depend on elimination of the opal codon.

Since no structure has been described for the alphavirus nsP4 protein, when we isolated SVPZF, we generated a molecular model of this protein. Although molecular models have obvious limitations, especially when the test protein and the template protein are not closely related, they may be useful in localizing amino acid residues to specific domains of a protein. In the case of SVPZF, we localized one changed residue to the finger domain and the other two to the thumb domain. In the case of SVCPC, the single changed amino acid was localized to the thumb domain. If our molecular model is valid, it is noteworthy that in neither case were the mutations in the catalytic site, i.e., in the palm region of nsP4.

We undertook the isolation of SVPZF and SVCPC with the expectation that the replicase/transcriptase enzymes encoded by these viruses would have an increased affinity for UTP and CTP in the first case, and perhaps only for CTP in the second case. This idea is supported by our finding that the SVCPC replicase/transcriptase has a Km for CTP approximately fivefold lower than that of the SVSTD replicase/transcriptase, whereas the Kms for UTP are very similar. This is the first report of an SV mutant (or possibly of any positive-strand RNA virus mutant) that encodes a replicase or transcriptase with a decreased Km for one of its rNTP substrates.

The question arises of whether these are the only mutations that can give rise to the phenotypes we were seeking. We have shown that in addition to a Phe substitution for Leu, a Tyr substitution can also result in resistance to CPC. Of particular interest is our finding that SVPZF is cross-resistant to CPC but SVCPC is not cross-resistant to PZF. This suggests that specific amino acid changes may selectively alter the affinity of the viral RDRP for individual rNTP substrates and that each of these rNTPs makes contact with different amino acid residues of the RDRP. Although it might be expected that changes in the RDRP that alter its affinity for the rNTP substrates would occur mainly in amino acid residues that make direct contact with these substrates or lie in proximity to the residues that do, there is evidence that amino acid changes in the finger and thumb domains can alter the conformation of the catalytic site or the specificity of a polymerase for nucleoside analogs of the rNTPs (5, 15).

We have identified specific amino acid residues that are altered in the nsP4 proteins encoded by SVPZF and SVCPC. Future work will be directed at identifying other amino acid changes in nsP4 that permit the virus to replicate in cells with decreased levels of one or more of the rNTP substrates. SVPZF and SVCPC are novel viral mutants that were selected for their ability to replicate in cells with reduced levels of rNTPs. Further study of these mutants should lead to important information bearing on viral replication and should provide insights useful for the development of viral vectors (6) and novel inhibitors of viral replication.


   ACKNOWLEDGMENTS
 
We thank Michael Newlon for help with the figures and Yan Hu for technical support.

This work was funded by U.S. Public Health Service grant AI-49273.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08854. Phone: (732) 235-4596. Fax: (732) 235-5223. E-mail: stollar{at}umdnj.edu. Back

{dagger} Present address: Wyeth-Lederle Vaccines, Pearl River, NY 10965. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ahola, T., and L. Kaariainen. 1995. Reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc. Natl. Acad. Sci. USA 92:507-511.[Abstract/Free Full Text]
  2. Barton, D. J., S. G. Sawicki, and D. L. Sawicki. 1988. Demonstration in vitro of temperature-sensitive elongation of RNA in Sindbis virus mutant ts6. J. Virol. 62:3597-3602.[Abstract/Free Full Text]
  3. Barton, D. J., Sawicki, S. G., and D. L. Sawicki. 1991. Solubilization and immunoprecipitation of alphavirus replication complexes. J. Virol. 65:1496-1506.[Abstract/Free Full Text]
  4. Bofill, M., L. D. Fairbanks, K. Ruckemann, M. Lipman, and H. A. Simmonds. 1995. T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection. J. Biol. Chem. 270:29690-29697.[Abstract/Free Full Text]
  5. Boyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.[Abstract/Free Full Text]
  6. Dubensky, T. W., Jr., D. A. Driver, J. M. Polo, B. A. Belli, E. M. Latham, C. E. Ibanez, S. Chada, D. Brumm, T. A. Banks, S. J. Mento, D. J. Jolly, and S. M. Chang. 1996. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:508-519.[Abstract]
  7. Durbin, R. K., and V. Stollar. 1984. A mutant of Sindbis virus with a host-dependent defect in maturation associated with hyperglycosylation of E2. Virology 135:331-344.[CrossRef][Medline]
  8. Durbin, R. K., and V. Stollar. 1985. Sindbis virus mutants able to replicate in methionine-deprived Aedes albopictus cells. Virology 144:529-533.[CrossRef][Medline]
  9. Fairbanks, L. D., M. Bofill, K. Ruckemann, and H. A. Simmonds. 1995. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270:29682-29689.[Abstract/Free Full Text]
  10. Fata, C. L., S. G. Sawicki, and D. L. Sawicki. 2002. Alphavirus minus-strand RNA synthesis: identification of a role for Arg183 of the nsP4 polymerase. J. Virol. 76:8632-8640.[Abstract/Free Full Text]
  11. Ford, H., Jr., D. A. Cooney, G. S. Ahluwalia, Z. Hao, M. E. Rommel, L. Hicks, K. A. Dobyns, J. E. Tomaszewski, and D. G. Johns. 1991. Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts. Cancer Res. 51:3733-3740.[Abstract/Free Full Text]
  12. Gomez, M. D., N. Ehsani, M. L. Mikkola, J. A. Garcia, and L. Kaariainen. 1999. RNA helicase activity of Semliki Forest virus replicase protein NSP2. FEBS Lett. 448:19-22.[CrossRef][Medline]
  13. Hardy, W. R., and J. H. Strauss. 1989. Processing the nonstructural polyproteins of Sindbis virus: nonstructural proteinase is in the C-terminal half of nsP2 and functions both in cis and in trans. J. Virol. 63:4653-4664.[Abstract/Free Full Text]
  14. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.[Abstract/Free Full Text]
  15. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.[Abstract/Free Full Text]
  16. Lemm, J. A., A. Bergqvist, C. M. Read, and C. M. Rice. 1998. Template-dependent initiation of Sindbis virus RNA replication in vitro. J. Virol. 72:6546-6553.[Abstract/Free Full Text]
  17. Lemm, J. A., T. Rumenapf, E. G. Strauss, J. H. Strauss, and C. M. Rice. 1994. Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis. EMBO J. 13:2925-2934.[Medline]
  18. Li, G. P., and C. M. Rice. 1989. Mutagenesis of the in-frame opal termination codon preceding nsP4 of Sindbis virus: studies of translational readthrough and its effect on virus replication. J. Virol. 63:1326-1337.[Abstract/Free Full Text]
  19. Li, M. L., and V. Stollar. 1995. A mutant of Sindbis virus which is released efficiently from cells maintained in low ionic strength medium. Virology 210:237-243.[CrossRef][Medline]
  20. Lin, Y. H., P. Yadav, R. Ravatn, and V. Stollar. 2000. A mutant of Sindbis virus that is resistant to pyrazofurin encodes an altered RNA polymerase. Virology 272:61-71.[CrossRef][Medline]
  21. Mi, S., R. Durbin, H. V. Huang, C. M. Rice, and V. Stollar. 1989. Association of the Sindbis virus RNA methyltransferase activity with the nonstructural protein nsP1. Virology 170:385-391.[CrossRef][Medline]
  22. Poch, O., I. Sauvaget, M. Delarue, and N. Tordo. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8:3867-3874.[Medline]
  23. Rice, C. M., R. Levis, J. H. Strauss, and H. V. Huang. 1987. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants. J. Virol. 61:3809-3819.[Abstract/Free Full Text]
  24. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
  25. Scheidel, L. M., R. K. Durbin, and V. Stollar. 1987. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158:1-7.[CrossRef][Medline]
  26. Scheidel, L. M., and V. Stollar. 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181:490-499.[CrossRef][Medline]
  27. Schlesinger, S., and M. J. Schlesinger. 2001. Togaviridae, p. 567-588. In D. M. Knipe and P. M. Howley (ed.), Fundamental virology, 4th ed. The Williams & Wilkins Co., Philadelphia, Pa.
  28. Shenk, T. E., and V. Stollar. 1973. Defective-interfering particles of Sindbis virus. II. Homologous interference. Virology 55:530-534.
  29. Shirako, Y., and J. H. Strauss. 1994. Regulation of Sindbis virus RNA replication: uncleaved P123 and nsP4 function in minus-strand RNA synthesis, whereas cleaved products from P123 are required for efficient plus-strand RNA synthesis. J. Virol. 68:1874-1885.[Abstract/Free Full Text]
  30. Stollar, V., and F. Malinoski. 1981. The effects of adenosine and guanosine on the replication of Sindbis and vesicular stomatitis viruses in Aedes albopretus cells. Virology 115:57-66.[CrossRef][Medline]
  31. Stollar, V., B. D. Stollar, R. Koo, K. A. Harrap, and R. W. Schlesinger. 1976. Sialic acid contents of Sindbis virus from vertebrate and mosquito cells. Equivalence of biological and immunological viral properties. Virology 69:104-115.[CrossRef][Medline]
  32. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:491-562.[Abstract/Free Full Text]
  33. Vasiljeva, L., A. Merits, P. Auvinen, and L. Kaariainen. 2000. Identification of a novel function of the alphavirus capping apparatus. RNA 5'-triphosphatase activity of Nsp2. J. Biol. Chem. 275:17281-17287.[Abstract/Free Full Text]
  34. Wang, Q. M., M. A. Hockman, K. Staschke, R. B. Johnson, K. A. Case, J. Lu, S. Parsons, F. Zhang, R. Rathnachalam, K. Kirkegaard, and J. M. Colacino. 2002. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76:3865-3872.[Abstract/Free Full Text]

Journal of Virology, September 2004, p. 9645-9651, Vol. 78, No. 18
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.18.9645-9651.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, M.-L.
Right arrow Articles by Stollar, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, M.-L.
Right arrow Articles by Stollar, V.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS